Skip to main content
Premium Trial:

Request an Annual Quote

Flemish Government Provides $2.5M to Biocartis to Develop Cancer Tests

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis today announced a €1.9 million ($2.5 million) subsidy from the Flemish government for the development of diagnostic cancer tests.

The funding is for a two-year period, during which Biocartis will develop tests to run on its fully automated system. The tests will be directed at the detection of known, validated oncogenes "and allow for more targeted treatment of certain cancers," Biocartis said.

The company plans to focus on skin, colon, and lung cancer. It will also seek to develop tests to simultaneously detect "dozens of parameters" for use on its Dynamic Multi-Analyte Technology, or DMAT, platform, a multiplex detection platform for the research market.

The system was launched in December. At the time the company announced the completion of a $45 million Series D financing round.

"Oncology is our company’s primary focus for the development of diagnostic tests," Erwin Sablon, head of Applied Assay Development for Biocartis, said in a statement. "This grant will speed up the development of a broad range of clinically relevant tests that will help make cancer treatment more efficient and personalized as well as improve survival rates for patients."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.